COVID-19

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

Naturally acquired SARS-CoV-2 immunity persists for up to 11 months following infection

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

The incubation period distribution of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Increased transmissibility and global spread of SARSCoV-2 variants of concern as at June 2021

Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in SARS-CoV-2 infected patients: a single center study

Immunological imprinting of the antibody response in COVID-19 patients

In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies

Dysregulation of brain and choroid plexus cell types in severe COVID-19

Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial

Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died

Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19